Interaction Checker

Alteplase interactions

Alteplase (Activase, Cathflo Activase) has 91 documented interactions across the FDA labels and fact sheets we index: 0 major, 40 moderate, 51 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Moderate interactions (40)

  • Amlodipine and benazeprildihydropyridine calcium channel blockerModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • ApixabananticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

  • ArgatrobananticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

  • AspirinNSAIDModerate

    Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Alteplase label, Warnings and precautions)

  • Aspirin and dipyridamoleantiplatelet agentModerate

    Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Alteplase label, Warnings and precautions)

  • BenazeprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Benazepril and hydrochlorothiazideACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • BivalirudinanticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

  • Butalbital, aspirin, and caffeinebarbiturateModerate

    Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Alteplase label, Warnings and precautions)

  • Butalbital, aspirin, caffeine, and codeinebarbiturateModerate

    Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Alteplase label, Warnings and precautions)

  • Cangrelorantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • CaptoprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Cilostazolantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • Clopidogrelantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • DabigatrananticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

  • Dipyridamoleantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • EdoxabananticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

  • EnalaprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Enalapril and hydrochlorothiazideACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • EnalaprilatACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • EnoxaparinanticoagulantModerate

    Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Alteplase label, Warnings and precautions)

  • Eptifibatideantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • FondaparinuxanticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

  • FosinoprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Fosinopril and hydrochlorothiazideACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • HeparinanticoagulantModerate

    Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Alteplase label, Warnings and precautions)

  • LisinoprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Lisinopril and hydrochlorothiazideACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • MoexiprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Orphenadrine, aspirin, and caffeinemuscle relaxantModerate

    Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. (Alteplase label, Warnings and precautions)

  • PerindoprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Prasugrelantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • QuinaprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • Quinapril and hydrochlorothiazideACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • RamiprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • RivaroxabananticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

  • Ticagrelorantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • Tirofibanantiplatelet agentModerate

    Anticoagulants and antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Activase therapy. (Alteplase label, Drug interactions)

  • TrandolaprilACE inhibitorModerate

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (Alteplase label, Drug interactions)

  • WarfarinanticoagulantModerate

    …hemorrhagic ophthalmic conditions Septic thrombophlebitis or occluded AV cannula at seriously infected site Advanced age [see Use in Specific Populations (8.5) ] Patients currently receiving anticoagulants (e.g., warfarin sodium) Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location. (Alteplase label, Warnings and precautions)

Minor mentions (51)

  • Articaine and epinephrinelocal anestheticMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • AzelastineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Azelastine and fluticasoneantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • BeclomethasonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • BetamethasonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Brompheniramine, pseudoephedrine, and dextromethorphanantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • BudesonidecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Bupivacaine and epinephrinelocal anestheticMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • CarbinoxamineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • CetirizineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • ChlorpheniramineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • CiclesonidecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • ClemastineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • ClobetasolcorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • CyproheptadineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DeflazacortcorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DesloratadineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DesonidecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DexamethasonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DexchlorpheniramineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DimenhydrinateantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DiphenhydramineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • DoxylamineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Doxylamine and pyridoxineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • EpinephrinesympathomimeticMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • FexofenadineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • FludrocortisonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • FlunisolidecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • FluocinonidecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • FluticasonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • HalobetasolcorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Hydrocodone and chlorpheniramineopioidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • HydrocortisonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • HydroxyzineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • LevocetirizineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Lidocaine and epinephrinelocal anestheticMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • LoratadineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • MeclizineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • MethylprednisolonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • MometasonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • OlopatadineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Olopatadine and mometasoneantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • PrednisolonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • PrednisonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Prilocaine and epinephrinelocal anestheticMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • PromethazineantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Promethazine and codeineopioidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • Promethazine and dextromethorphanantihistamineMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

  • TriamcinolonecorticosteroidMinor

    If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (Alteplase label, Warnings and precautions)

Check Alteplase against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.